Silo Pharma, Inc. (SILO) Dividend History

Company News

• Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

  Silo Pharma announced positive results from an initial study of its SP-26 ketamine extended-release implant for chronic pain and fibromyalgia, with no serious side effects observed. The company expects final safety and absorption data in March 2025.

  GlobeNewswire Inc.
• Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

  Silo Pharma is making progress in developing its lead assets SPC-15 and SP-26 for the treatment of PTSD, stress-induced anxiety, and chronic pain. The company is preparing to submit an IND for SPC-15 in 2025 and is advancing animal studies for SP-26 ketamine implants.

  GlobeNewswire Inc.
• Silo Pharma secures $2.1 million in direct offering - Investing.com

  Silo Pharma, a biopharmaceutical company, has announced a $2.1 million direct offering to fund its work on novel therapies for psychiatric disorders, chronic pain, and CNS diseases. The company has made advancements in its Alzheimer's and PTSD drug development programs.

  Investing.com
• Gold Down 2%; SLB Posts Upbeat Earnings - Benzinga

  U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 300 points. Schlumberger reported better-than-expected second-quarter results, with revenue and adjusted EPS beating consensus estimates.

  Benzinga

  Featured Companies: HE KITT SLB SXTP
• Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire

  Silo Pharma, a biopharmaceutical company, announced a $2.1 million registered direct offering of common stock and warrants. The company plans to use the proceeds for working capital and general corporate purposes.

  GlobeNewswire Inc.